Search Results

search

Search Filters

Organization
AAVantgarde Bio
aavantgarde_logo.jpg
AAVantgarde Founder and Chief Scientific Officer, Professor Alberto Auricchio, is elected as President of the European Society of Gene and Cell Therapy
October 28, 2024 03:00 ET | AAVantgarde Bio
AAVantgarde Founder and Chief Scientific Officer, Professor Alberto Auricchio, is elected as President of the European Society of Gene and Cell Therapy
aavantgarde_logo.jpg
AAVantgarde appoints Ms. Lauren Kaskiel as Chief Business Officer
October 21, 2024 02:00 ET | AAVantgarde Bio
AAVantgarde appoints Ms. Lauren Kaskiel as Chief Business Officer
aavantgarde_logo.jpg
AAVantgarde announces 3 oral presentations at ESGCT 2024 annual meeting
October 08, 2024 02:00 ET | AAVantgarde Bio
MILAN, Oct. 08, 2024 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage, Italian-based international biotechnology company with two proprietary Adeno-Associated Viral (AAV) vector...
aavantgarde_logo.jpg
AAVantgarde appoints Dr. Jayashree Sahni as Chief Medical Officer
September 09, 2024 02:00 ET | AAVantgarde Bio
AAVantgarde appoints Dr. Jayashree Sahni as Chief Medical Officer
aavantgarde_logo.jpg
AAVantgarde announces its innovative clinical study design for its lead program in Usher 1B
May 03, 2024 03:00 ET | AAVantgarde Bio
AAVantgarde announces its innovative clinical study design for its lead program in Usher 1B
aavantgarde_logo.jpg
AAVantgarde announces updated NHP data from its Stargardt disease program in a poster presentation at the ARVO 2024 annual meeting
April 24, 2024 02:00 ET | AAVantgarde Bio
AAVantgarde announces updated NHP data from its Stargardt disease program in a poster presentation at the ARVO 2024 annual meeting
aavantgarde_logo.jpg
AAVantgarde presents positive preclinical data in large animal models from its Stargardt disease program in an oral presentation at the ASGCT 2024 annual meeting
April 23, 2024 02:00 ET | AAVantgarde Bio
AAVantgarde presents positive preclinical data in large animal models from its Stargardt disease program in an oral presentation at ASGCT 2024
AAVANTAGARDE BIO LOGO_low_res.jpg
AAVantgarde Closes €61 Million Series A Financing to Advance Two Therapeutic Programs into the Clinic
June 06, 2023 08:00 ET | AAVantgarde Bio
- Financing led by Atlas Venture and Forbion - Company created, incubated and seed financed by Sofinnova Partners MILAN, Italy, June 06, 2023 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a...